1. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Issue 3 (March 2018) Authors: Torres, Antoni; Zhong, Nanshan; Pachl, Jan; Timsit, Jean-François; Kollef, Marin; Chen, Zhangjing; Song, Jie; Taylor, Dianna; Laud, Peter J; Stone, Gregory G; Chow, Joseph W Journal: Lancet infectious diseases Issue: Volume 18:Issue 3(2018) Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 3, Randomized, Double-blind Noninferiority (NI) Study of Ceftazidime–Avibactam (CAZ-AVI) vs. Meropenem (MER) in the Treatment of Patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE Study per US FDA Endpoints. (4th October 2017) Authors: Torres, Antoni; Rank, Doug; Rekeda, Ludmyla; Chen, Xiang; Riccobene, Todd; Critchley, Ian; Lakkis, Hassan; Melnick, David; Chow, Joseph W; Taylor, Dianna; Laud, Peter J; Talley, Angela K Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗